PARP1 and cholangiocarcinoma: Alterations in DDR-related genes such as BRCA1/2, PARP, ATM, ATR, BAP1, ARID1A, RAD51, MLH1, TP53 makes CCA an optimal candidate for DDRi treatment, a well-established therapy in clinical application today.